Pulse Biosciences (NASDAQ:PLSE) Shares Up 9.3% – Here’s What Happened

Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) were up 9.3% during trading on Friday . The stock traded as high as $17.63 and last traded at $17.62. Approximately 109,554 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 201,550 shares. The stock had previously closed at $16.12.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research report on Tuesday, November 12th.

Pulse Biosciences Trading Up 9.7 %

The business’s 50-day moving average is $17.22 and its 200-day moving average is $15.32.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the prior year, the business earned ($0.19) EPS.

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in shares of Pulse Biosciences by 63.6% in the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after buying an additional 2,952 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in Pulse Biosciences in the 1st quarter valued at about $88,000. Quest Partners LLC bought a new position in shares of Pulse Biosciences in the second quarter worth about $91,000. Cetera Advisors LLC acquired a new position in shares of Pulse Biosciences during the first quarter worth approximately $109,000. Finally, Rhumbline Advisers grew its stake in shares of Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after purchasing an additional 1,608 shares during the last quarter. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.